COME CONTRIBUIRE

FONDAZIONE

PUBBLICAZIONI SCIENTIFICHE


IMPACT FACTOR

L'impact factor dei lavori scientifici è attualmente di 2143.60 punti considerando l'I.F. più recente della rivista


I risultati delle ricerche finanziate dalla Associazione in questi anni sono stati presentati in numerosi convegni e congressi nazionali ed internazionali e pubblicati su importanti riviste scientifiche.
  • Rivista:
  • Journal Clinical Oncology Global Oncology (ISSN 2687-8941), 11-e2500139, 2025

158 – Impact of Ethnicity on Breast Cancer Outcome: A Systematic Review and Meta-Analysis of Randomized Phase III Trials of the Last Decade

  • AUTORI: Zattarin E., Moscetti L., D'Agostino E., Bertolotti A., Sperduti I., Chiavelli C., Canino F., Piacentini F., Cortesi L., Dominici M., Toss A.
Abstract Purpose: It remains uncertain whether ethnicity affects the benefit derived from novel breast cancer (BC) treatments. Thus, we conducted a systematic review and meta-analysis
  • Rivista:
  • Communications Medicine - London (ISSN 2730-664X), 5:1-70, 2025

156 – Reduced reproductive potential in young healthy women with hereditary breast and/or ovarian cancer syndrome

  • AUTORI: Sighinolfi G., Grandi G., Barbieri E., Venturelli M., Piombino C., Melotti C., Lippi Bruni R., Costantini Cuoghi R., D'Amico R., Lambertini M., Peccatori F.A., Tenedini E., Dominici M., Cortesi L., La Marca A., Toss A.
Abstract Background: Young, healthy women carrying a pathogenic or likely pathogenic variant (P/LPV) in genes configuring the hereditary breast and/or ovarian cancer (HBOC) syndrome face
  • Rivista:
  • Cancer Treatment Reviews (ISSN 0305-7372), 126-102723, 2024

155 – Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer

  • AUTORI: D'Agostino E., Mastrodomenico L., Ponzoni O., Baldessari C., Piombino C., Pipitone S., Giuseppa Vitale M., Sabbatini R., Dominici M., Toss A.
Abstract Endometrial cancer (EC) incidence and mortality rates have been increasing, particularly among young females. Although more than 90% of ECs are sporadic, 5-10%
  • Rivista:
  • Cancer Medicne (ISSN 2045-7634), 14:22-e71377, 2025

154 – A Decade of Specialized Acute Care: Clinical Impact of an Oncology-Hematology Emergency Room Compared to General Emergency Services

  • AUTORI: Malavasi N., Ferrara L., Di Marco L., Saviola A., Postiglione R., Cantile F., Acquaviva G., Galassi L., Bergonzini A., Fiorani C., Scarabelli L., Dominici M., Luppi M., Longo G.
Abstract Background: The management of severe complications arising from newly diagnosed or existing cancer, as well as acute therapy-related side effects, is traditionally provided by
  • Rivista:
  • Journal Clinical of Oncology Global Oncology (ISSN 2687-8941), 11:e2400344, 2025

153 – Cause- Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study

  • AUTORI: Cabrera M.E., Civallero M., Stepanishyna Y., Derio L., Skrypets T., Lois V., Vega V., Calderon S., Rojas H., Pizarro A., Mendoza M.G., Romero M., Rojas C., Oliva J., Intriago M., Rojas B., Conte L., Marcheselli L., Federico M.
Abstract Purpose: Hodgkin lymphoma (HL) is classified as the first malignancy to be cured by a combination of chemotherapy and radiotherapy. However, the life expectancy
  • Rivista:
  • Hemasphere (ISSN 2572-9241), 9:4-e70105, 2025

152 – High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial

  • AUTORI: Gotti M., Yana Stepanishyna Y., Tetiana Skrypets T., Marcheselli L., Cristinelli C., Botto B., Tonino S., Cavalieri D., Pulsoni A., Hutchings M., Hammoud M., Fortpied C., Rigacci L., Plattel W., Andrè M., Federico M.
No abstract available
  • Rivista:
  • Cancer Reports (ISSN: 2573-8348), 7:12-e70028, 2O24

151 – Low Incidence of Cancer Recorded in the Galapagos Archipelago

  • AUTORI: Chisesi S.N., Rugge M., Galli G.R., Manni M., Luzuriaga Delgado V.M., Chisesi, T., Ruiz J.C., Mariuxi R., Briones Q., Siculella L., Guzzinati S., Zorzi M., Federico M., Iannone A.
Abstract Background: Cancer incidence in the Galapagos archipelago is unknown. Aim: In 2021, a task force including Ecuadorian and Italian researchers was established to estimate cancer
  • Rivista:
  • British Journal of Haematology (ISSN 0007-1048), 205:1-166:174, 2024

150 – Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project

  • AUTORI: Monica Civallero, Joseph G Schroers-Martin, Steven Horwitz, Martina Manni, Yana Stepanishyna, Maria Elena Cabrera, Julie Vose, Michele Spina, et al.
Abstract Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable
  • Rivista:
  • British Journal of Haematology (ISNN 0007-1048), 204:5-1757:1761, 2024

149 – Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021

  • AUTORI: Yana Stepanishyna, Martina Manni, Monica Civallero, Nazar Shokun, Tetiana Skrypets, Alevtyna Burtna, Natalia Shapovalenko, et al.
Abstract We report the outcome of 563 cases of newly diagnosed lymphoma registered in 2019-2021, including 176 cases (31.2%) of Hodgkin lymphoma (HL), 130
  • Rivista:
  • Clinical Case Report (ISSN 2050-0904), 11:8-e7747, 2023

148 – Management of PALB2-associated breast cancer: a literature review and case report

  • AUTORI: Toss A., Ponzoni O., Riccò B., Piombino C., Moscetti L., Combi F., Palma E., Papi S., Tenedini E., Tazzioli G., Dominici M., Cortesi L.
Abstract Germline pathogenic variants (PV) of the PALB2 tumor suppressor gene are associated with an increased risk of breast, pancreatic, and ovarian cancer. In previous research, PALB2-associated
  • Rivista:
  • Oncologist (ISSN 1083-7159), 28:10-e884:e890, 2023 - I.F. 5,8

147 – Healthcare professional communication on sexual health: a report from the Italian Working Group on adolescents and young adults with cancer

  • AUTORI: Quarello P., Toss A., Berchiella P., Mascarin M., Lambertini M., Canesi M., Milano G.M., Incorvaia L., Banna G.L., Peccatori F., Ferrari A.
Abstract Background: Sexual function is an important concern for adolescent and young adult (AYA) with cancer. The aim of this study was to explore the
  • Rivista:
  • ESMO Open (ISSN 2059-7029), 2023 - I.F. 7,3

145 – A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)

  • AUTORI: Cortesi L., Venturelli M., Cortesi G., Caggia F., Toss A., Barbieri E., De Giorgi U., Guarneri V., Musolino A., De Matteis E., Zambelli A., Bisagni G., Dominici M.
Abstract Background BRCA1/2-related metastatic breast cancers (mBC) are sensitive to DNA-damage agents and show high tumor-infiltrated lymphocytes. We hypothesized that the association between pembrolizumab
  • Rivista:
  • Hematology Oncology (ISSN 1099-1069), 41:4-655:662, 2023

144 – Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naive advanced-stage follicular lymphoma: a subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi

  • AUTORI: Nizzoli M.E., Manni M., Ghiggi C., Pulsoni A., Musuraca G., Merli M., Califano C., Bari A., Massaia M., Conconi A., Musto P., Mannina D., Perrone T., Re F., Galimberti S., Gini G., Capponi M., Vitolo U., Usai S.V., Stefani P.M., Ballerini F., Liberati A.M
Abstract We conducted a post hoc analysis of the FOLL12 trial to determine the impact of different initial immunochemotherapy (ICT) regimens on patient outcomes.
  • Rivista:
  • Frontiers in Oncology 12-10162958, 2022 - I.F. 4,7

142 – Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy

  • AUTORI: Toss A., Venturelli M., Civallero M., Piombino C., Domati F., Ficarra G., Combi F., Cabitza E., Caggia F., Barbieri E., Bartolini M., Moscetti L., Omarini C., Piacentini F., Tazzioli G., Dominici M., Cortesi L.
Abstract Introduction: Triple-negative breast cancer (TNBC) patients who do not obtain pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) present higher rate of relapse and
  • Rivista:
  • Hematological Oncology 40-5:953-961, 2022 - I.F. 4,85

141 – Characteristics and clinical outcomes of patients with ALK- Positive anaplastic large cell lymphoma: report from the Prospective International T-Cell Lymphoma Project

  • AUTORI: Chiattone C., Civallero M., Fischer T., Miranda M., Zing N.P.C., Pileri S.A., Montoto S., Horwitz S.M., Cabrera M.E., De Souza C.A., Nagler A., Luminari S., Ferreri A.J.M., Carson K.R., Re A., Rigacci L., Nassi L., Stepanishyna Y., Federico M., Inghiran
Abstract The T-cell Lymphoma Project is an international registry prospective study that enrolled patients with newly diagnosed peripheral T-cell and NK-cell lymphomas (PTCL). The
  • Rivista:
  • Cancer, 2021 - I.F. 5,73

139 – Insights into the possible molecular mechanisms of resistance to PARP inhibitors

  • AUTORI: Piombino C., Cortesi L.
Abstract PARP1 enzyme plays an important role in DNA damage recognition and signalling. PARP inhibitors are approved in breast, ovarian, pancreatic, and prostate cancers
  • Rivista:
  • Frontieres in Oncology-Breast Cancer, 2021 - I.F. 5,73

138 – Obesity in postmenopausal breast cancer patients: it is time to improve actions for a healthier lifestyle

  • AUTORI: Cortesi L., Galli G.R., Domati F., Conte L., Manca L., Berio M.A., Toss A., Iannone A., Federico M.
Abstract Background: Adult body fatness is a convincing risk factor for postmenopausal breast cancer. With the aim to compare the different breast cancer (BC)
  • Rivista:
  • Journal of Clinical Oncology 40-7:729-739, 2021 - I.F. 44,54

136 – Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study

  • AUTORI: Luminari S., Manni M., Galimberti S., Versari A., Tucci A., Boccomini C., Farina L., Olivieri J., Marcheselli L., Guerra L., Ferrero S., Arcaini L., Cavallo F., Kovalchuk S., Skrypets T., Del Giudice I., Chauvie S., Patti C., Stelitano C., Ricci F., Pinto
Abstract Purpose: We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction
  • Rivista:
  • Genes 12:5-616, 2021 - I.F. 3,75

133 – Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers

  • AUTORI: Toss A., Tenedini E., Piombino C., Venturelli M., Marchi I., Gasparini E., Barbieri E. et al.
Abstract: The most common breast cancer (BC) susceptibility genes beyond BRCA1/2 are ATM and CHEK2. For the purpose of exploring the clinicopathologic characteristics of
  • Rivista:
  • Biomedicines 9:3-312, 2021 - I.F. 4,71

132 – The Role of Exosomes in Breast Cancer Diagnosis

  • AUTORI: Piombino C., Mastrolia I., Omarini C., Candini O., Dominici M., Piacentini F., Toss A.
Abstract: The importance of molecular re-characterization of metastatic disease with the purpose of monitoring tumor evolution has been acknowledged in numerous clinical guidelines for
  • Rivista:
  • Diagnostic 11:3-565, 2021 - I.F. 5,25

131 – The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study

  • AUTORI: Toss A., Piombino C., Tenedini E., Bologna A., Gasparini E., Tarantino V., Filieri ME. et al.
Abstract: Previous research involving epithelial ovarian cancer patients showed that, compared to germline BRCA (gBRCA) mutations, somatic BRCA (sBRCA) mutations present a similar positive
  • Rivista:
  • Cancer Biology and Medicine, 18:2-470:476, 2021 - I.F. 5,43

129 – BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees

  • AUTORI: Cortesi L., Domati F., Guida A., Marchi I., Toss A., Barbieri E., Marcheselli L. et al.
Objective: As prostate cancer (PrC) shows a BRCA mutation rate as high as 30%, it becomes crucial to find the optimal selection criteria for
  • Rivista:
  • Journal of Oncology, 2020 - I.F. 4,37

128 – Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA

  • AUTORI: Piombino C., Cortesi L., Lambertini M., Punie K., Grandi G., Toss A.
BRCA1- and BRCA2-associated hereditary breast and ovarian cancer syndromes are among the best-known and most extensively studied hereditary cancer syndromes. Nevertheless, many patients who
  • Rivista:
  • ESMO Open 6:2, 2021 - I.F. 4,93

127 – Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era

  • AUTORI: Toss A., Isca C., Venturelli M., Nasso C., Ficarra G., Bellelli V., Armocida C. et al.
Introduction: The present analysis aims to evaluate the consequences of a 2-month interruption of mammographic screening on breast cancer (BC) stage at diagnosis and
  • Rivista:
  • British Journal of Haematology 192:6-1011:1014, 2021 - I.F. 5,02

126 – Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma

  • AUTORI: Massaro F., Stepanishyna Y., Manni M., Luminari S., Galimberti S., Marcheselli L., Visco C. et al.
Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R-HCVAD regimen [rituximab plus HyperCVAD
  • Rivista:
  • Cancers 12:5-1252, 2020 - I.F. 6,12

124 – BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy

  • AUTORI: Toss A., Molinaro E., Venturelli M., Domati F., Marcheselli L., Piana S. et al.
NCCN Guidelines recommend BRCA genetic testing in individuals with a probability >5% of being a carrier. Nonetheless, the cost-effectiveness of testing individuals with no
  • Rivista:
  • International Journal of Molecular Sciences 19:8-2337, 2018 - I.F. 4,55

121 – The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease

  • AUTORI: Cosenza M., Pozzi S.
Histone deacetylases (HDACs) are master regulators of chromatin remodeling, acting as epigenetic regulators of gene expression. In the last decade, inhibition of HDACs has
  • Rivista:
  • Journal of Clinical Oncology 36:7-689:696, 2018 - I.F. 28,24

121 – Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma

  • AUTORI: Luminari S., Ferrari A., Manni M., Dondi A., Chiarenza A., Merli F. et al.
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab
  • Rivista:
  • Cancers 11:2-193:204, 2019 - I.F. 6,12

119 – Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies

  • AUTORI: Toss A., Venturelli M., Molinaro E., Pipitone S., Barbieri E., Marchi I., Tenedini E., Artuso L., Castellano S., Marino M., Tagliafico E., Razzaboni E., De Matteis E., Cascinu S., Cortesi L.
The identification of BRCA mutations plays a crucial role in the management of hereditary cancer prevention and treatment. Nonetheless, BRCA-testing in pancreatic cancer (PC)
  • Rivista:
  • Frontiers in Oncology 8-254, 29 - I.F. 4,41

118 – LonP1 differently modulates mitochondrial function and bioenergetics of primary versus metastatic colon cancer cells

  • AUTORI: Gibellini L., Losi L., De Biasi S., Nasi M., Lo Tartaro D. et al
Mitochondrial Lon protease (LonP1) is a multi-function enzyme that regulates mitochondrial functions in several human malignancies, including colorectal cancer (CRC). The mechanism(s) by which
  • Rivista:
  • British Journal of Haematology 181:6-760:769, 2019 - I.F. 6,99

117 – Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), AS new prognostic model developed by the International T-cell Project Network

  • AUTORI: Federico M., Bellei M., Marcheselli L., Schwartz M., Manni M., Tarantino V. et al
Different models to investigate the prognosis of peripheral T cell lymphoma not otherwise specified (PTCL-NOS) have been developed by means of retrospective analyses. Here
  • Rivista:
  • Oncotarget 8:61-103797:103814, 2017 - I.F. 3,33

114 – Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases

  • AUTORI: Civallero M., Cosenza M., Pozzi S., Sacchi S.
JAK-2 dysregulation plays an important role as an oncogenic driver, and is thus a promising therapeutic target in hematological malignancies. Ruxolitinib is a pyrrolo[2.3-d]pyrimidine
  • Rivista:
  • Oncology 93:6-377:386, 2017 - I.F. 2,93

114 – Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo- Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study

  • AUTORI: Cortesi L., De Matteis E., Toss A., Marchi I., Medici V., Contu G. et al.
Objective: To evaluate the effectiveness of transvaginal ultrasound (TVU) and serum CA-125 measurement in women at different risk of developing ovarian cancer/fallopian tube cancer
  • Rivista:
  • Hematological Oncology 35:4-630:636, 2016 - I.F. 5,27

111 – Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study

  • AUTORI: Bellei M., Sabattini E., Pesce EA., Ko YH., Kim WS., Cabreras ME. et al.
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation with different
  • Rivista:
  • BioMed Research International 1:12, 2015 - I.F. 3,41

108 – Activity of BKM120 and BEZ235 against lymphoma cells

  • AUTORI: Civallero M., Cosenza M., Pozzi S., Bari A., Ferri P., Sacchi S.
Non-Hodgkin lymphomas encompass a heterogeneous group of cancers, with 85–90% arising from B lymphocytes and the remainder deriving from T lymphocytes or NK lymphocytes.

RICERCA SUL CANCRO

PUBBLICAZIONI SCIENTIFICHE

Tutti i nostri articoli pubblicati sulle riviste scientifiche
VAI

PROGETTI DI RICERCA

I progetti di ricerca che abbiamo sostenuto
VAI

BORSE DI STUDIO E STAGE ALL'ESTERO

Borse di studio e stage all'estero per ricercatori finanziati dall'Associazione
VAI

PREMI DI STUDIO

Premi di studio per la ricerca contro i tumori
VAI

PREMIO "PIER CAMILLO BECCARIA"

Conferito ogni anno ad un illustre studioso che si è distinto nella lotta contro i tumori
VAI